MedPath

The Effects of Lactobacillus Rhamnosus (JB-1) on Stress and Cognition

Not Applicable
Completed
Conditions
Healthy
Interventions
Dietary Supplement: Lactobacillus Rhamnosus (JB-1)
Dietary Supplement: Placebo
Registration Number
NCT03160066
Lead Sponsor
University College Cork
Brief Summary

Emerging evidence suggests that microorganisms acting via the Brain-Gut axis may have potential benefits for the management of stress-related conditions. The majority of studies have focused on animal models. Preclinical studies have identified the Lactobacillus Rhamnosus JB-1 strain as a putative psychobiotic with an impact on stress-related behaviours, physiology and cognitive performance. Whether such preclinical effects could be translated to healthy human volunteers remains unknown.

Detailed Description

30 healthy male volunteers will be recruited in a randomized single blind placebo controlled cross over trial. Study participation will involve a screening visit followed by a baseline cognitive test battery, EEG and stress visit (socially evaluated cold-pressor test). These measures will be repeated after 4 weeks of daily probiotic and placebo capsules.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
29
Inclusion Criteria
  • able to give informed written consent
  • able to speak English
Exclusion Criteria
  • having a significant acute or chronic illness
  • following a diet or taking a medication that would interfere with study objectives
  • pose a safety risk or confound the interpretation of the study results
  • evidence of immunodeficiency, bleeding disorder or coagulopathy
  • English not being participant's first language
  • colour blindness
  • dyslexia or dyscalculia
  • taking any probiotic products or antibiotics in the last 4 weeks
  • receiving any treatment involving experimental drugs

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
ActiveLactobacillus Rhamnosus (JB-1)Capsules containing 1x10\^9 colony forming units of Lactobacillus Rhamnosus (JB-1) will be given once per day for 4 weeks.
PlaceboPlaceboPlacebo capsules identical to the probiotic in taste, smell, colour, and comprised only of the same non-active ingredients (corn starch, magnesium stearate and silicon dioxide) in the probiotic supplement will be given once per day for 4 weeks.
Primary Outcome Measures
NameTimeMethod
Change in CognitionChange from Baseline, after 4 weeks of initial treatment and after 4 weeks of second treatment

A battery of cognitive tests will be assessed using the Cambridge Neuropsychological Test Automated Battery

Secondary Outcome Measures
NameTimeMethod
Change in the Inflammatory profileChange from Baseline, after 4 weeks of initial treatment and after 4 weeks of second treatment

Cytokine levels and toll-like receptor activity

Change in Salivary cortisol concentrationsChange from Baseline, after 4 weeks of initial treatment and after 4 weeks of second treatment

Salivary cortisol will be collected before and after the socially evaluated cold pressor procedure.

Changes in MoodChange from Baseline, after 4 weeks of initial treatment and after 4 weeks of second treatment

Beck Depression Inventory

Changes in AnxietyChange from Baseline, after 4 weeks of initial treatment and after 4 weeks of second treatment

Beck Anxiety Inventory

Change in Electroencephalography (EEG)Change from Baseline, after 4 weeks of initial treatment and after 4 weeks of second treatment

EEG measures of absolute power in the delta (1.5-3.5Hz), theta (4-7.5Hz), alpha1 (8- 9.5Hz), alpha2 (10-12.5Hz), beta1 (13-17.5Hz), and beta2 (18-25.5Hz) frequency bands

Changes in Stress levelsChange from Baseline, after 4 weeks of initial treatment and after 4 weeks of second treatment

Perceived Stress Scale

Trial Locations

Locations (1)

APC Microbiome Institute

🇮🇪

Cork, Ireland

© Copyright 2025. All Rights Reserved by MedPath